1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24738
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKosmidis, P. A.en
dc.contributor.authorSyrigos, K.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorBoukovinas, I.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorBacoyiannis, C.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:43:17Z-
dc.date.available2015-11-24T19:43:17Z-
dc.identifier.issn1791-7530-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24738-
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma/drug therapy/mortality/secondaryen
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectBone Neoplasms/drug therapy/mortality/secondaryen
dc.subjectBrain Neoplasms/drug therapy/mortality/secondaryen
dc.subjectCarcinoma, Large Cell/diagnosis/geneticsen
dc.subjectCarcinoma, Non-Small-Cell Lung/*drug therapy/*mortality/secondaryen
dc.subjectCarcinoma, Squamous Cell/drug therapy/mortality/secondaryen
dc.subjectDisease Progressionen
dc.subjectFemaleen
dc.subjectFollow-Up Studiesen
dc.subjectHumansen
dc.subjectLiver Neoplasms/drug therapy/mortality/secondaryen
dc.subjectLung Neoplasms/drug therapy/mortality/pathologyen
dc.subjectLymphatic Metastasisen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Recurrence, Local/*drug therapy/mortality/pathologyen
dc.subjectNeoplasm Stagingen
dc.subjectPaclitaxel/administration & dosageen
dc.subjectSmall Cell Lung Carcinoma/drug therapy/mortality/secondaryen
dc.subjectSurvival Rateen
dc.subjectTreatment Outcomeen
dc.subjectVinblastine/administration & dosage/analogs & derivativesen
dc.titleVinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2en
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/22213304-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2012-
heal.abstractAIM: The purpose of this study was to compare two single agents paclitaxel (intravenous) versus vinorelbine (oral) in non-small cell lung cancer (NSCLC) patients with performance status (PS):2. PATIENTS AND METHODS: The patients were randomized to receive either oral vinorelbine 60 mg/m(2) on days 1, 8, 15 every 4 weeks for 4 cycles (group A) or paclitaxel 90 mg/m(2) intravenously for 1 h on days 1, 8, 15 every 4 weeks for a total of 4 cycles (group B). RESULTS: Among the 74 eligible patients (36 in arm A and 38 in arm B) in arm A, two (6%) had a partial response (95% CI, 0.7-18.7) and 5 (14%) had stable disease (95% CI, 4.7-29.5). In arm B, five (13%) had a partial response (95% CI, 4.4-28.1) and 7 (18%) had stable disease (95% CI, 7.7-34.3). No significant difference was found in terms of clinical benefit between the two groups after two cycles of treatment except for appetite in favour of paclitaxel (p=0.01). Median survival was 3.1 months (95% CI, 2.2-4.0) for arm A and 5.1 months (95% CI, 2.7-7.6) for arm B (p=0.95). Toxicity was mild and only alopecia was more profound in the patients of arm B (p=0.008). CONCLUSION: No significant difference was found in clinical benefit between PS:2 NSCLC patients treated with either vinorelbine or paclitaxel.en
heal.journalNameAnticancer Resen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons